dian improvement in GFR of 99.4% (IQR 69.9 to 160%). Pre-implant cardiac index (p0.20), inotrope use (p0.47), loop diuretic use (p0.55) and diabetes (p0.9) were not associated with IRF. Pts with an elevated BUN/Cr had significantly increased incidence of IRF (OR1.5, p0.001). This association persisted after adjustment for baseline GFR (OR1.5, p0.001) and adjustment for baseline characteristics associated with IRF (hemoglobin, heart rate, systolic blood pressure, ACE inhibitor use, beta blocker use, edema, race, INTERMACS class, and sodium; OR1.5, p0.002). Conclusions: HF pts with an elevated pre-implant BUN/Cr are more likely to experience post-LVAD IRF. The ability to appropriately distinguish pts with reversible from those with irreversible RI, utilizing markers such as BUN/Cr, could potentially facilitate use of advanced therapies in pts previously not considered candidates due to their RI. Additional research aimed at identification of pts with potential for significant IRF is warranted. 111 Outcomes of Patients with Anthracycline Cardiomyopathy Treated with Mechanical Circulatory Support: Data from the INTERMACS Registry G.H. Oliveira, 1 D. Matthias, 1 D.C. Naftel, 2 Y. Yuan, 2 S.L. Meyers, 2 D. Schmuhl, 1 M.M. Mountis, 1 N. Smedira, 1 W.W.H. Tang, 1 G. Gonzalez-Stawinski, 1 D.O. Taylor, 1 R.C. Starling. 11 Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH; 2 Department of Biostatistics, University of Alabama, Birmingham, AL. Purpose: Cancer patients(pts) treated with anthracyclines(AC) may de- velop AC-induced cardiomyopathy requiring advanced therapy. Mechani- cal circulatory support(MCS) is an important option because malignancy may preclude transplantation eligibility. Yet there are no data to support use of MCS in AC pts. We describe the safety and outcome of AC pts treated with MCS. Methods and Materials: We analyzed prospectively entered INTERMACS data, including pts 19 yrs with diagnosis of AC between 6/2006 and 3/2011. Baseline characteristics, implant strategies, adverse events were compared between AC and non-ischemic(NI) pts. Adjusted survival analysis was performed using established MCS risk factors. Results: The prevalence of AC was 2%(75/3812 pts). Compared to other NI, AC pts were predominantly female(72 vs 24%, p0.0001), more tachycardic(100 vs 92/min, p0.0001), had reduced LVEDD(5.9 vs 7.0cm, p0.0001), higher right atrial pressure(16 vs 13 mmHg, p0.01) and more frequent severe tricuspid regurgitation(62 vs 49%, p0.04), suggesting more frequent RV failure (RVF). Consequently the use of BiVAD in AC pts was higher than in the rest of the population (15 vs 8%, p0.05) and trended to be higher than in other NI pts (15 vs 10%, p0.19). Destination therapy was more common in AC pts (33.3 vs 14.4%, p0.0001). Compared to other NI, AC pts had more bleeding (p0.01), but similar rates of infection, renal failure and right HF post-implantation. Risk-adjusted analysis showed comparable 1 and 2 year survival in AC pts. Conclusions: AC pts with end-stage HF receiving MCS have similar outcomes as other MCS-treated pts, but appear to be at higher bleeding risk. There appears to be more pre-implant RVF and trend towards higher BiVAD use. 112 Identification of Non-HLA Antibodies in Ventricular Assist Device Recipients M.J. Barten, 1 D. Dragun, 2 S. von Salisch, 1 M.-T. Dieterlen, 1 J. Garbade, 1 S. Klein, 1 S. Dhein, 1 F.W. Mohr, 1 H.B. Bittner. 1 1 Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany; 2 Clinic for Nephrology and Intensive Care Medicine, Charité- Universitätsmedizin Berlin, Berlin, Germany. Purpose: t is known that patients bridged to heart transplantation with ventricular assist device (VAD) have a higher incidence to develop anti- bodies directed against human leukocyte (HLA). Both HLA antibodies and non-HLA antibodies like major histocompatibility complex class I-related chain A (MICA) and functional autoantibodies against angiotensin type 1 receptor (AT1R) and endothelin receptor A (ETAR) are implicated in pathogenesis of acute rejection (AR) and cardiac allograft vasculopathy (CAV). Therefore, in this study we monitored HLA and non-HLA anti- bodies in VAD recipients (VADR) during the first year after VAD-implan- tation. Methods and Materials: Sera of 29 VAD-recipients were analyzed by Luminex for HLA and MICA (cut-off 3) and by ELISA for AT1R and ETAR antibodies (cut-off 17 Units). Blood transfusions, VAD-type, gender and age were reviewed. Results: The average age of the group was 53.613.4 years (26 men). The majority of VADR were positive for AT1R (65.5%) and ETAR (68.9%) antibodies. Of note, most of the VADR showed extremely high antibody titres up to 1000 U (27.6% each) or up to 2000 U (AT1R: 24.1%; ETAR: 34.5%). Almost half of the VADR, 48.2%, were with moderate titres positive for HLA and/or MICA antibodies within the first year, whereas 27.5% were positive for HLA-class I antibodies, 24.1% for HLA-class II antibodies and 17.2% for MICA antibodies. No significant difference in the number of received blood products were observed between antibody- negative or -positive VADR, but AT1R/ETAR positive VADR received a higher amount of blood transfusions (55.577.6 vs. 16.19.5). Conclusions: This study revealed for the first time the incidence of non- HLA antibodies in VADR. Since AT1R/ETAR and MICA antibodies were shown to be involved in the pathogenesis of acute rejection and CAV, screening for both antibody types should be included in clinical routine. The large proportion of patients having high-titre of AT1R/ETAR antibod- ies may indicate immunological high-risk patients, which warrants partic- ular attention. 113 Improvement in Functional Capacity after Left Ventricular Assist Device Therapy Can Be Limited by Preoperative Comorbidities M.S. Kiernan, 1 D.T. Pham, 1 N.K. Kapur, 1 N.L. Pereira, 2 K.S. Sundareswaran, 3 M. Stueber, 5 D.J. Farrar, 3 D. DeNofrio, 1 J.G. Rogers. 41 Cardiology, Tufts Medical Center, Boston, MA; 2 Cardiology, Mayo Clinic, Rochester, MN; 3 Thoratec Corporation, Pleasanton, CA; 4 Cardiology, Duke University Medical Center, Durham, NC; 5 Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany. Purpose: Left ventricular assist device (LVAD) therapy significantly im- proves functional capacity (FC) in advanced heart failure patients (pts); however, approximately 20% of LVAD pts continue to experience New York Heart Association (NYHA) class III-IV symptoms. Methods and Materials: Preoperative clinical, laboratory, hemodynamic variables, and previously defined risk scores of right ventricular (RV) function from pts enrolled in the HeartMate II bridge-to-transplantation (BTT) or destination-therapy (DT) clinical trials (n713) were evaluated using multi-variable logistic regression to identify predictors of improved FC. Only pts supported for at least 6 months were included. “Responders” were defined by post-operative NYHA I/II symptoms, improvement in 6-minute-walk distance (6MWD) from baseline to 6 months  70 meters (m), or 6MWD  220m at 6 months (if no baseline available). Results: All pts had baseline class IIIB / IV symptoms. Overall, 83% of pts were considered FC “responders” to LVAD therapy. Responders had longer support durations compared to non-responders (835  489 vs. 723  443 days; p0.012). Compared to BTT, a greater proportion of DT pts were S46 The Journal of Heart and Lung Transplantation, Vol 31, No 4S, April 2012